Abata's autologous Treg cell therapies are engineered to express T cell receptors (TCRs) that recognize antigens present in tissue where an autoimmune response has been triggered. This enables Abata's Tregs to target the site of disease for a robust effect without imposing systemic immune suppression.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/23/21 | $95,000,000 | Series A |
ElevateBio Invus JDRF T1D Fund Samsara BioCapital Third Rock Ventures  | undisclosed |
